Stockscreener 앱 받기
83.67
3.68%
2.9641
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics Q1 2026 earnings preview - MSN
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX) - The Globe and Mail
Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR) - The Globe and Mail
Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $119 - Moomoo
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration - Yahoo Finance
HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera Therapeutics, Inc. (KYMR) reports Q1 loss, tops revenue estimates - MSN
Kymera Q1 2026 slides: immunology pipeline advances, revenue surges By Investing.com - Investing.com Australia
Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - GuruFocus
KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS - MarketBeat
Kymera Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Key Risks and Forward-Looking Statements in Kymera Therapeutics, Inc. Q1 2026 10-Q Report - Minichart
Kymera Therapeutics Q1 Earnings Call Highlights - MarketBeat
Kymera Therapeutics Reports Q1 2026 Financial Results, Highlights Pipeline Progress and $1.55B Cash Runway into 2029 - Minichart
Kymera shifts KT-579 data to 2H 2026, keeps KT-621 on track - MSN
Kymera Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts By Investing.com - Investing.com Australia
Kymera Therapeutics (KYMR) Achieves Strong Q1 Revenue Performanc - GuruFocus
Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts - Investing.com
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Investing News Network
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Is Kymera Therapeutics (KYMR) 418.1% Overvalued After Q1 2026 Be - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat - ChartMill
Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss - marketscreener.com
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M - marketscreener.com
Kymera Therapeutics (NASDAQ: KYMR) grows collaboration revenue but stays in loss - Stock Titan
Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan
Kymera has $1.55B to fund asthma and dermatitis drug trials - Stock Titan
Pictet Asset Management Holding SA Has $37.79 Million Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative - Sahm
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Stock - MarketBeat
Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock - Investing.com
Kymera (KYMR) CEO Mainolfi exercises options and sells 30,000 shares under 10b5-1 plan - Stock Titan
[ARS] Kymera Therapeutics, Inc. SEC Filing - Stock Titan
Kymera Therapeutics (NASDAQ: KYMR) outlines 2026 director, pay and auditor votes - Stock Titan
Kymera Therapeutics earnings on deck after Gilead deal milestone - Investing.com UK
Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com - Investing.com South Africa
How Investors May Respond To Kymera Therapeutics (KYMR) FDA Fast Track Win And Gilead Trial Expansion - simplywall.st
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q1 202 - GuruFocus
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 - Investing News Network
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
B. Metzler seel. Sohn & Co. AG Purchases New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress - Yahoo Finance
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - msn.com
0.83%
2.04%
자본화:
|
볼륨(24시간):